Your browser is no longer supported. Please, upgrade your browser.
IQV IQVIA Holdings Inc. monthly Stock Chart
IQVIA Holdings Inc.
IndexS&P 500 P/E241.80 EPS (ttm)0.67 Insider Own0.40% Shs Outstand191.60M Perf Week1.76%
Market Cap30.78B Forward P/E21.34 EPS next Y7.55 Insider Trans-89.98% Shs Float186.19M Perf Month11.70%
Income132.00M PEG23.10 EPS next Q1.53 Inst Own93.00% Short Float1.34% Perf Quarter18.83%
Sales10.94B P/S2.81 EPS this Y-11.10% Inst Trans0.47% Short Ratio2.07 Perf Half Y0.32%
Book/sh28.92 P/B5.57 EPS next Y22.23% ROA0.80% Target Price184.17 Perf Year3.73%
Cash/sh5.18 P/C31.09 EPS next 5Y10.47% ROE3.20% 52W Range81.79 - 169.14 Perf YTD4.23%
Dividend- P/FCF36.86 EPS past 5Y-18.80% ROI3.60% 52W High-4.79% Beta1.33
Dividend %- Quick Ratio1.10 Sales past 5Y15.20% Gross Margin33.40% 52W Low96.89% ATR3.74
Employees67000 Current Ratio1.10 Sales Q/Q2.60% Oper. Margin6.90% RSI (14)60.41 Volatility1.59% 2.49%
OptionableYes Debt/Eq2.18 EPS Q/Q45.70% Profit Margin1.70% Rel Volume0.96 Prev Close161.04
ShortableYes LT Debt/Eq2.16 EarningsJul 22 BMO Payout0.00% Avg Volume1.20M Price161.04
Recom1.80 SMA203.09% SMA508.59% SMA20012.86% Volume0 Change0.00%
Jul-07-20Initiated Stephens Equal-Weight $150
Mar-02-20Initiated Deutsche Bank Buy $190
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Dec-13-19Upgrade CFRA Sell → Hold
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Jun-21-19Upgrade Mizuho Neutral → Buy $150 → $175
May-28-19Initiated SVB Leerink Outperform
Jan-18-19Upgrade Jefferies Hold → Buy
Oct-09-18Initiated UBS Buy
Oct-02-18Reiterated Robert W. Baird Outperform $143 → $146
Jul-25-18Upgrade BofA/Merrill Neutral → Buy
Jul-25-18Reiterated Stifel Buy $128 → $150
Jul-03-18Upgrade Raymond James Outperform → Strong Buy
Apr-13-18Upgrade Goldman Neutral → Buy
Mar-07-18Upgrade SunTrust Hold → Buy
Jan-19-18Initiated Evercore ISI Outperform $112
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-31-20 11:09AM  
Jul-30-20 11:40AM  
Jul-29-20 08:00AM  
Jul-25-20 10:39AM  
Jul-23-20 08:00AM  
Jul-22-20 01:00PM  
Jul-21-20 06:12PM  
Jul-20-20 08:01AM  
Jul-17-20 11:27AM  
Jul-15-20 12:31PM  
Jul-14-20 11:07AM  
Jul-08-20 04:15PM  
Jul-02-20 08:00AM  
Jun-23-20 06:14PM  
Jun-09-20 09:24AM  
Jun-03-20 08:00AM  
Jun-02-20 10:58AM  
Jun-01-20 10:07AM  
May-28-20 01:18PM  
May-27-20 07:14PM  
May-26-20 03:54PM  
May-21-20 08:00AM  
May-20-20 08:00AM  
May-11-20 10:08AM  
May-07-20 11:52AM  
May-01-20 08:36AM  
Apr-29-20 09:20AM  
Apr-28-20 06:01PM  
Apr-27-20 09:43AM  
Apr-24-20 12:28PM  
Apr-23-20 05:49AM  
Apr-22-20 03:04PM  
Apr-07-20 09:28AM  
Apr-06-20 07:00PM  
Apr-03-20 03:00PM  
Apr-02-20 08:29PM  
Mar-26-20 01:15PM  
Mar-24-20 08:00AM  
Mar-13-20 11:30AM  
Mar-12-20 12:41PM  
Mar-09-20 03:34PM  
Mar-07-20 10:31AM  
Feb-24-20 02:59PM  
Feb-20-20 08:49AM  
Feb-19-20 06:56AM  
Feb-17-20 06:31PM  
Feb-13-20 04:41PM  
Feb-12-20 01:13PM  
Feb-11-20 07:57AM  
Feb-05-20 12:30PM  
Feb-04-20 12:10PM  
Feb-03-20 08:00AM  
Jan-30-20 08:00AM  
Jan-29-20 04:15PM  
Jan-23-20 09:21AM  
Jan-21-20 08:00AM  
Jan-15-20 11:00PM  
Jan-08-20 07:37AM  
Jan-07-20 07:34AM  
Jan-03-20 09:07AM  
Jan-02-20 12:01AM  
Dec-26-19 12:07PM  
Dec-24-19 12:59PM  
Dec-19-19 08:00AM  
Dec-04-19 11:40AM  
Nov-30-19 03:01PM  
Nov-27-19 11:08AM  
Nov-26-19 06:20AM  
Nov-25-19 12:40PM  
Nov-15-19 01:13PM  
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bruehlman Ronald ESee RemarksAug 04Buy159.9410,0001,599,40026,751Aug 05 05:02 PM
TPG Group Holdings (SBS) AdvisFormer DirectorJul 28Sale159.122,919,051464,479,3950Jul 29 04:42 PM
BOUSBIB ARISee RemarksJul 22Sale160.0046,0807,372,800652,035Jul 24 05:09 PM
BOUSBIB ARISee RemarksJun 02Sale150.11164,87724,749,686652,035Jun 04 05:35 PM
BOUSBIB ARISee RemarksJun 01Sale150.0019,4432,916,450652,035Jun 03 05:35 PM
EVANISKO MICHAEL JDirectorMar 24Option Exercise21.206,600139,92011,850Mar 26 05:00 PM
Knightly Kevin CSee RemarksFeb 21Sale163.432,191358,0750Feb 25 05:02 PM
Knightly Kevin CSee RemarksFeb 19Sale165.095,688939,0322,191Feb 20 05:03 PM
STAUB W RICHARDSee RemarksFeb 18Option Exercise78.2118,2241,425,29935,953Feb 20 05:05 PM
STAUB W RICHARDSee RemarksFeb 18Sale163.7714,5502,382,85421,403Feb 20 05:05 PM
TPG Group Holdings (SBS) AdvisDirectorFeb 13Sale164.302,996,172492,271,0602,919,051Feb 18 07:00 PM
CONNAUGHTON JOHNDirectorFeb 13Sale164.30703,828115,638,940685,712Feb 18 04:29 PM
EVANISKO MICHAEL JDirectorJan 31Option Exercise23.706,250148,12511,500Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 31Sale155.196,250969,9385,250Feb 04 05:02 PM
EVANISKO MICHAEL JDirectorJan 24Option Exercise20.316,250126,92511,500Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 24Sale159.076,250994,1885,250Jan 28 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Option Exercise18.406,250115,00011,500Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 17Sale160.766,2501,004,7505,250Jan 21 05:00 PM
EVANISKO MICHAEL JDirectorJan 10Option Exercise18.406,250115,00011,500Jan 14 04:56 PM
EVANISKO MICHAEL JDirectorJan 10Sale160.086,2501,000,5005,250Jan 14 04:56 PM
MCDONNELL MICHAEL REVP and CFOJan 02Sale155.0712,0001,860,84014,366Jan 06 05:05 PM
LEONARD JOHN M.DirectorDec 20Option Exercise64.7720,2001,308,25428,452Dec 26 04:33 PM
LEONARD JOHN M.DirectorDec 20Sale153.0020,2003,090,6008,252Dec 26 04:33 PM